Evidence map›Paper›PMID 40244226›Full record

ArticleInternational journal of molecular sciences2025

Hillmin Lei, Ali Shawki, Alina N Santos, Vinicius Canale, Salomon Manz, Meli'sa S Crawford, Pritha Chatterjee, Marianne R Spalinger, Michael Scharl, Declan F McCole

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hillmin LeiSchool of Medicine, Division of Biomedical Sciences, University of California, Riverside, CA 92521, USA.ORCID 0000-0003-1719-1387
Ali ShawkiSchool of Medicine, Division of Biomedical Sciences, University of California, Riverside, CA 92521, USA.
Alina N SantosSchool of Medicine, Division of Biomedical Sciences, University of California, Riverside, CA 92521, USA.
Vinicius CanaleSchool of Medicine, Division of Biomedical Sciences, University of California, Riverside, CA 92521, USA.ORCID 0000-0002-2030-0268
Salomon ManzSchool of Medicine, Division of Biomedical Sciences, University of California, Riverside, CA 92521, USA.ORCID 0000-0003-1062-5189
Meli'sa S CrawfordSchool of Medicine, Division of Biomedical Sciences, University of California, Riverside, CA 92521, USA.ORCID 0000-0003-1766-3751
Pritha ChatterjeeSchool of Medicine, Division of Biomedical Sciences, University of California, Riverside, CA 92521, USA.
Marianne R SpalingerSchool of Medicine, Division of Biomedical Sciences, University of California, Riverside, CA 92521, USA.ORCID 0000-0003-4498-0058
Michael ScharlDepartment of Gastroenterology & Hepatology, University Hospital Zurich, 8091 Zurich, Switzerland.
Declan F McColeSchool of Medicine, Division of Biomedical Sciences, University of California, Riverside, CA 92521, USA.ORCID 0000-0002-6286-0802

Funding

A NOVEL ROLE FOR PTPN2 IN INTESTINAL EPITHELIAL BARRIER REGULATIONR01DK091281 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Declan McCole · 2012 to 2026
$5.5M
Tyrosine Phosphatase Regulation of Mucosal Macrophage-Epithelial Cell Cross-talkR01AI153314 · NIAID · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI MCCOLE, DECLAN · 2020 to 2024
$2.5M
Targeted Identification of IBD Risk Gene Variant Impact on Immune-Epithelial Crosstalk and Intestinal Barrier FunctionR01DK138456 · NIDDK · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI Declan McCole · 2024 to 2026
$1.3M
Inflammatory Bowel Disease Susceptibility Gene Regulation of AnemiaR21AI152017 · NIAID · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI MCCOLE, DECLAN · 2021 to 2022
$428k
NIAID NIH HHS R01 AI153314NIAID NIH HHS R21 AI152017NIDDK NIH HHS R01 DK091281NIDDK NIH HHS R01 DK138456NIH HHS 1R01AI153314-01NIH HHS 1R01DK138456-01NIH HHS 2R01-DK091281NIH/NIAID R21AI152017Swiss National Science Foundation Advanced Postdoctoral Mobility Grant 177932UCR-City of Hope CUBRI Award 2016
6 · The paper itself

Abstract

Anemia is the most common extraintestinal manifestation of inflammatory bowel disease (IBD). Iron deficiency is the most frequent cause of anemia in IBD; however, the mechanisms involved are still poorly understood. Here, we investigated the role of the IBD risk gene, protein tyrosine phosphatase non-receptor type 2 (

Indexed as

Anemia, Iron-DeficiencyInflammatory Bowel DiseasesIronIron DeficienciesProtein Tyrosine Phosphatase, Non-Receptor Type 2AdultAnimalsCation Transport ProteinsDisease Models, AnimalFemaleHomeostasisHumansMaleMiceMice, Inbred C57BLMice, KnockoutCation Transport ProteinsIronProtein Tyrosine Phosphatase, Non-Receptor Type 2PTPN2 protein, humanPtpn2 protein, mouseSolute Carrier Family 11, Member 2anemiainflammatory bowel diseaseiron deficiency

Identifiers

PMID40244226
PMCPMC11989999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.